Client

NorChip AS

Klokkarstua, Norway

www.norchip.com

Synopsis

Client

NorChip AS, Klokkarstua, Norway

Developing and marketing PreTect® HPV-Proofer, a cost-effective diagnostic assay for the detection of cervical cancer in women of all ages, identifying the expression of E6/E7 mRNA coding for HPV proteins E6/E7 from HPV types 16, 18, 31, 33 and 45.

Mandate

Board Advisory Services

Our Role

Retained advisor to the Board of Directors and management

  • Attended Board meetings in person or via conference call.
  • Advised on strategy and competitive position of the PreTect® HPV-Proofer assay.
  • Consulted management on investor outreach and ongoing fundraising efforts.
  • Accompanied management to meetings with prospective strategic partners and collaborators.

N.B. Consulting services performed prior to the formation of CATALYSIS CAPITAL PARTNERS LTD. and authorisation and regulation by FCA UK